ERNA Ernexa Therapeutics Inc. Forecast, Technical & Fundamental Analysis
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs... Show more
ERNA is expected to report earnings to rise 70.16% to -210 cents per share on August 17
Q2'26
Est.
$-2.11
Q4'22
Missed
by $1.10
Q3'22
Missed
by $0.29
Q2'22
Beat
by $0.07
Q1'22
Beat
by $0.04
The last earnings report on March 20 showed earnings per share of -124 cents, missing the estimate of -14 cents. With 48.11K shares outstanding, the current market capitalization sits at 5.23M.
A.I. Advisor
published General Information
General Information
a developer of biomedical research products in the field of stem cells and regenerative medicine
A.I.dvisor indicates that over the last year, ERNA has been loosely correlated with MDGL. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ERNA jumps, then MDGL could also see price increases.
ERNA in upward trend: price may jump up because it broke its lower Bollinger Band on July 21, 2026
ERNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 42 cases where ERNA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ERNA's RSI Oscillator exited the oversold zone, of 54 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on August 06, 2026. You may want to consider a long position or call options on ERNA as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ERNA just turned positive on August 05, 2026. Looking at past instances where ERNA's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
Following a +3 3-day Advance, the price is estimated to grow further. Considering data from situations where ERNA advanced for three days, in of 196 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 29 cases where ERNA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ERNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ERNA entered a downward trend on July 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.762) is normal, around the industry mean (20.179). P/E Ratio (0.006) is within average values for comparable stocks, (26.004). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.625). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (1250.000) is also within normal values, averaging (463.689).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ERNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ERNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
